[Effects of glutamine given through different avenues on intestine mucosal barrier function in burned rats].
OBJECTIVE
To observe the effect of glutamine given through different avenues on intestine mucosal barrier damage induced by severe burn injury.


METHODS
One hundred and sixty Wistar rats were randomly divided into four groups: namely normal control (C group), burned control (B group), parenteral nutrition with glutamine (PN+GLN group) and enteral nutrition with glutamine (EN+GLN group). Rats in B group, PN+GLN group, and EN+GLN group were subjected to 30% total body surface area (TBSA) full-thickness burn injury. In the latter three groups, nutritional intake was isonitrogenous and isocaloric. In PN+GLN group and EN+GLN group the nutrition were supplemented with glutamine 1.0 g.kg(-1).d(-1), and in B group tyrosine 1.0 g.kg(-1).d(-1). Indexes relevant to injury to the intestine were determined on postburn day (PBD) 1, 3, 5, 7 and 10.


RESULTS
After burn injury, the index of intestinal mucosal injury, intestine mucosal permeability and the activity of plasma diamine oxidase (DAO) were significant increased compared with C group (all P<0.01). On the other hand, the intestine mucosal blood flow (IMBF), mucosa thickness, villous height, crypt depth and intestinal epithelial proliferation index were significantly decreased (P<0.05 or P<0.01). Compared with B group, the extent of changes in these indices were lowered in PN+GLN group and EN+GLN group (P<0.05 or P<0.01), and the effects were more marked in EN+GLN group than those in PN+GLN group.


CONCLUSIONS
GLN is beneficial in minimizing intestinal injury, promoting intestinal mucosal repair. Enteral supplementation of GLN is a better way of administration.
Lü
Shang-jun
SJ
Institute of Burn Research, Southwest Hospital, Third Medical University, State Key Laboratory of Trauma, Burn and Combined Injury, Chongqing 400038, China. lvshangjun@163.com
Peng
Xi
X
Zhang
Yong
Y
Sun
Yong
Y
You
Zhong-yi
ZY
D000818:Animals; D002056:Burns / Q000503:physiopathology* / Q000628:therapy; D004195:Disease Models, Animal; D004750:Enteral Nutrition; D005260:Female; D005973:Glutamine / Q000008:administration & dosage* / Q000627:therapeutic use; D007413:Intestinal Mucosa / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D010288:Parenteral Nutrition; D010539:Permeability / Q000187:drug effects; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D005973:Glutamine